Matinas BioPharma Holdings, Inc. (MTNB) stock
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $13.37M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$6.69M
- EPS, diluted
- -$1.21
- Book value per share
- $0.28
- Diluted shares
- 6M
Trading
- Previous close
- $0.86
- Open
- $0.89
- Day's range
- $0.87 – $0.91
- Volume
- 5,849
- Average volume (20 days)
- 55,260
- 52-week range
- $0.81 – $18.02
- RSI (14 days)
- 29.1
- Volatility (1 year)
- 125.7%
- Relative volume
- 0.02×
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | MTNB | S&P 500 | Difference | MTNB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -61.6% | -4.3% | −57.3 pts | ||
| 3 months | -70.2% | -4.6% | −65.6 pts | ||
| Year to date | -89.6% | +7.9% | −97.6 pts | ||
| 1 year | -94.9% | +11.8% | −106.7 pts | ||
| 3 years | -99.5% | +68.0% | −167.4 pts | -82.7% | +18.9% |
| 5 years | -99.9% | +66.2% | −166.1 pts | -74.2% | +10.7% |
| 10 years | -99.9% | +291.3% | −391.2 pts | -51.0% | +14.6% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Matinas BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- News
- News
- News
About Matinas BioPharma
Pharmaceutical Preparations
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies utilizing its proprietary lipid nanocrystal delivery technology. The platform encapsulates small molecules and oligonucleotides to facilitate targeted, extrahepatic cellular delivery without toxicity, targeting applications in oncology and inflammation. The company's lead product candidate is MAT2203, an oral formulation of the potent antifungal agent amphotericin B engineered to treat life-threatening invasive fungal infections, including invasive aspergillosis, cryptococcal meningitis, and invasive candidiasis. The company develops these therapeutic candidates primarily for patients facing serious fungal infections who have limited or no alternative treatment options.
Company profile, executives and historyMatinas BioPharma stock: common questions
What is Matinas BioPharma's stock price?
MTNB closed at $0.91 on Nov 18, 2026, up 6.35% on the day. Over the past 52 weeks it traded between $0.81 and $18.02.
What is Matinas BioPharma's market cap?
Matinas BioPharma was worth $13.37M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is MTNB's P/E ratio?
Matinas BioPharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.21), so it has no meaningful P/E ratio.
Does Matinas BioPharma pay a dividend?
No. Matinas BioPharma has not paid a cash dividend over the last twelve months.
How has MTNB stock performed over the past year?
Including dividends, MTNB returned -94.9% over the past year, against +11.8% for the S&P 500.
Who are Matinas BioPharma's competitors?
Companies most similar to Matinas BioPharma by business, industry and size include ABUS, LIPO, SCYX, HIND, ANTX.
See a number that looks wrong?